非甾体抗炎药物局部点眼辅助治疗AMD研究进展

摘要

治疗AMD的主要方法是玻璃体腔内注射抗血管内皮生长因子(VEGF)药物,但其最大的缺点是费用高、需要重复注药,一方面使经济困难的患者丧失了治疗机会,另一方面,反复眼内注射也增加了许多并发症的发生机会.因此,如何减少注药次数是该治疗最需要解决的问题.非甾体抗炎药(NSAID)具有抗炎、抗新生血管生成的作用,已有研究表明NSAID辅助抗VEGF药物治疗AMD可以提高治疗效果,减少抗VEGF药物玻璃体腔注药次数,并降低黄斑中心厚度.现对NSAID治疗CNV的机制以及动物实验和临床试验的相关研究进展进行综述,以期促进更多的眼科同仁关注此种辅助治疗方法,并开展更进一步的研究.%Intravitreous injection of vascular endothelial growth factor (VEGF) inhibition is the main method of wet age-related macular degeneration (AMD) treatment.The biggest drawback of this regimen is the high cost,which make poor people lose the treatment opportunity,and repeated drug injection,which increases the incidence of a lot of complications.Therefore,how to decrease the number of drug administration is the most urgent problem to solve.Non-steroidal anti-inflammatory drugs (NSAID) have the anti-inflammation and anti-angiogenesis effects.Previous studies have shown that NSAID as an adjunctive therapy of anti-VEGF drugs for AMD can improve the treatment effect,reduce the times of intravitreous injection of VEGF drugs,and reduce the central macular thickness.Thus,the mechanism of NSAID for CNV treatment and related progress in animal experiments and clinical trials were reviewed in this paper,in order to raise concerns of more ophthalmologist about this auxiliary treatment and to promote further researches.